重组人白介素-１１治疗化疗所致血小板减少的临床观察

目的：观察重组人白介素-１１（ｒｈＩＬ-１１）对恶性肿瘤患者因化疗所致血小板减少的疗效及毒副反应。方法：化疗后血小板低于２５×１０９／Ｌ给予ｒｈＩＬ-１１ ５０μｇ／（ｋｇ·ｄ）皮下注射，血小板低于５０×１０９／Ｌ给予ｒｈＩＬ-１１ ２５μｇ／（ｋｇ·ｄ）皮下注射，观察外周血小板变化，血小板升至≥７５×１０９／Ｌ时停药。结果：血小板升至≥７５×１０９／Ｌ所需时间：Ⅲ度２２例（５.０±１.３）天，Ⅳ度８例（１２.４±１.６）天。主要毒副反应为乏力、水肿、关节肌肉疼痛、注射部位疼痛。结论：重组人白介素-１１（ｒｈＩＬ-１１）有升高化疗后血小板减少的作用，毒副反应可耐受。

Clinical research of recombinant human interleukin-11 therapy for chemotherapy induced thrombocytopenia

Objective ：To observe the efficacy and side effects of recombinant human interleukin-11 （rhIL-11 ）in the treatment of thrombocytopenia caused by chemotherapy in patients with malignancies. Methods：Platelets after chemotherapy less than 30 × 10^9/L were injected subcutaneously with rhIL-11 501xg/（ kg.d）, platelets less than 50 × 10^9/L with rhIL-11 25μg/（kg·d） subcutaneous injection to observe changes in peripheral platelet until the counts of platelets came to 75 × 10^9/L. Results：Observed the time required to platelets increased to ≥75 × 10^9/L. The time to grade Ⅲ thrombocytopenia were（5.0 ± 1.3 ） days,and that of grade Ⅳ were（ 12.4 ±1.6） days. The main side effects including fatigue, edema,local pain of injection, arthralgia/muscular soreness. Conclusion： Recombinant human interleukin-11 （ rhIL-11 ） can elevate blood platelet count and a effective drug for treatment of thrombocytopenia caused by chemotherapy. Adverse reactions can be tolerated.